Immunosuppressive drugs after solid organ transplantation

Netherlands Journal of Medicine

Volumn 71, Issue 6, 2013, Pages 281-289

  van Sandwijk, M S ^a   Bemelman, F J ^a   ten Berge, I J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Immunosuppressive drugs; Renal transplantation; Solid organ transplantation

Indexed keywords

ALEMTUZUMAB; ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; ECULIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVEROLIMUS; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; ACUTE GRAFT REJECTION; ALLERGIC REACTION; ANTIBODY MEDIATED REJECTION; AUTOIMMUNE DISEASE; BK VIRUS INFECTION; BONE MARROW SUPPRESSION; CELL THERAPY; CUSHINGOID SYNDROME; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERPLASIA; HYPERTENSION; INFLAMMATION; INFUSION RELATED REACTION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); MOOD CHANGE; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CALCINEURIN; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; TOR SERINE-THREONINE KINASES;

EID: 84882266799     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Morris PJ. Transplantation - a medical miracle of the 20th century. N Engl J Med. 2004;351:2678-80.
2. Sayegh, MH, Carpenter CB. Transplantation 50 Years Later - Progress, Challenges, and Promises. N Engl J Med. 2004;351:2761-6.
3. Schwartz R, Eisner A, Dameshek W. The effect of 6-mercaptopurine on primary and secondary immune responses. J Clin Invest. 1959;38:1394-403.
4. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature. 1959;183:1682-3.
5. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med. 1963;268:1315-23.
6. Tilney NL. Transplant: from myth to reality. New Haven, Conn.: Yale University Press, 2003.
7. Hamilton D. Kidney transplantation: a history. In: Morris PJ, ed. Kidney transplantation: principles and practice. 5th ed. Philadelphia: W.B. Saunders, 2001:1-8.
8. Hamilton D. Reaching for the impossible: the quest for tissue replacement. In: Ginns LG, Cosimi AB, Morris PJ, eds. Transplantation. Boston: Blackwell Science, 1999:1-19.
9. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353:1711-23.
10. Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8:473-9.
11. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304-15.
12. ten Berge RJ, Sauerwein HP, Yong SL, Schellekens PT. Administration of prednisolone in vivo affects the ratio of OKT4/OKT8 and the LDH-isoenzyme pattern of human T lymphocytes. Clin Immunol Immunopathol. 1984;30:91-103.
13. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol. 1984;132:38-42.
14. Lanza L, Scudeletti M, Puppo F, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol. 1996;103:482-90.
15. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest. 1985;75:754-61.
16. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825-32.
17. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010;89:1-14.
18. ten Berge RJ, Schellekens PT, Surachno S, ten Veen JH, Wilmink JM. The influence of therapy with azathioprine and prednisone on the immune system of kidney transplant recipients. Clin Immunol Immunopathol. 1981;21:20-32.
19. ten Berge RJ, Schellekens PT, Surachno S, ten Veen JH, Wilmink JM. A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients. Clin Immunol Immunopathol. 1982;24:33-46.
20. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-45.
21. Janeway CA. Immunobiology. New York, NY: Garland Publishing, 2001.
22. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-29.
23. Knechtle SJ, Kwun J, Iwakoshi N. Prevention trumps treatment of antibody-mediated transplant rejection. J Clin Invest. 2010;120:1036-9.
24. Liu EH, Siegel RM, Harlan DM, O'Shea JJ. T cell-directed therapies: lessons learned and future prospects. Nat Immunol. 2007;8:25-30.
25. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008;8:1972-81.
26. Guba M, Graeb C, Jauch K, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777-82.
27. Randall T. New antirejection drugs anticipated. JAMA. 1990;264:1225.
28. Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): Mechanisms of action and effects in transplantation. Transplant Rev. 1993;7:129-40.
29. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991;33:161-73.
30. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443, a new, potent immunosuppressive agent. Transplantation. 1991;51:27-31.
31. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-32.
32. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-37.
33. Remuzzi G, Lesti M, Gotti E, et al Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet. 2004;364:503-12.
34. Remuzzi G, Cravedi P, Costantini M, et al Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007;18:1973-85
35. Elion GB, Callahan S, Nathan H. Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase, Biochem Pharmacol. 1963;12:85.
36. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227-43.
37. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695-7.
38. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990;1:162-79.
39. Ekberg H, Tedesco-Silva H, Demirbas A, et al. ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-75.
40. 4:CD003961.
41. Nourse J, Firpo E, Flanagan W, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-3.
42. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation. 1996;62:311-6.
43. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant. 2006;6:1617-23.
44. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075-85.
45. Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, Ten Berge IJ, Bemelman FJ. Everolimus-Treated Renal Transplant Recipients Have a More Robust CMV-Specific CD8+ T-Cell Response Compared With Cyclosporine- or Mycophenolate-Treated Patients. Transplantation. 2013;95:184-91.
46. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234-48.
47. Guerra G, Ciancio G, Gaynor JJ. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol. 2011;22:1758-68.
48. Lebranchu Y, Thierry A, Thervet E, et al, Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study. Am J Transplant. 2011;11:1665-75.
49. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233-42.
50. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitorfree regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377:837-47.
51. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387-94.
52. Brennan DC,Flavink K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67:1011-8.
53. Havenith SH, Remmerswaal EB, Bemelman FJ, et al. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. Clin Exp Immunol. 2012;169:292-301.
54. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3:137-43.
55. Bloom DD, Hu HZ, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of campath-1H-treated kidney transplant patients. Transplantation. 2006;81:81-7.
56. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573-9.
57. Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant. 2004;18:759-61.
58. Csapo Z, Benavides-Viveros C, Podder H, Pollard V, Kahan BD. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc. 2005;37:2032-6.
59. Basu A, Remkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005;37:923-6.
60. Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation. 2009;87:1092-5.
61. van den Hoogen MW, Hesselink DA, van Son WJ, Weimar W, Hilbrands LB. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant. 2013;13:192-6.
62. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibodymediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775-83.
63. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095-102.
64. Fuchinoue S, Ishii Y, Sawada T, et al, The 5-Year Outcome of ABO-Incompatible Kidney Transplantation With Rituximab Induction. Transplantation. 2011;91:853-7.
65. Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol. 2012;13:122-36.
66. Tydén G, Genberg H, Tollemar J, et al. A randomized, double blind, placebo-controlled study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009;87:1325-9.
67. Tydén G, Ekberg H, Tufveson G, Mjörnstedt L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation. 2012;94:e21-22.
68. Clatworthy MR, Watson CJE, Plotnek G, et al. B-cell depleting induction. N Engl J Med. 2009;360:2683-5.
69. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997;350:1193-8. [Erratum, Lancet 1997;350:1484.]
70. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation. 1999;67:276-84.
71. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;20:CD003897.
72. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-analysis. Transplantation. 2012;93:1179-88.
73. Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation. 2004;78:904-10.
74. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Thymoglobulin Induction Study Group Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967-77.
75. Brennan DC, Schnitzler MA, Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med. 2008;359:1736-8.
76. http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130945.pdf.
77. Arora S, Tangirala B, Osadchuk L, Sureshkumar KK. Belatacept: a new biological agent for maintenance immunosuppression in kidney transplantation. Expert Opin Biol Ther. 2012;12:965-79.
78. Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27:1246-51.
79. Sadaka B, Alloway RR, Woodle ES. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs. 2011;20:1535-42.
80. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256-64.
81. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibodymediated rejection in kidney transplantation. Nat Rev Nephrol. 2012;8:670-8.
82. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12:417-30.
83. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant. 2008;8:793-802.
84. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17:2844-53.
85. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177:8338-47.
86. Brunstein CG. MillerJS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-70.
87. http://www.onestudy.org/
88. Shin H-J, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood. 2011;118:2342-50.